2023-03-24T20:44:44-05:00 2022-06-30 910189318 MOSS ADAMS LLP 6565 AMERICAS PARKWAY NE STE 600 ALBUQUERQUE NM 87110 990 2021-09-25 850110669 LOVELACE BIOMEDICAL RESEARCH INSTITUTE LOVE 5053489361 2425 RIDGECREST DRIVE SE ALBUQUERQUE NM 87108 SHANNON TOMA CHIEF OPERATING OFFICER 5053489361 2023-03-24 1 SHANNON TOMA 999009999 PAMELA ALEXANDERSON P01218925 5058787200 2023-03-10 3 AAL1 IAL1 2021 2023-04-26 12:10:37Z ROBERT W RUBIN 2425 RIDGECREST DRIVE SE ALBUQUERQUE NM 87108 77028198 0 X WWW.LOVELACEBIOMEDICAL.ORG X 1965 NM THE LOVELACE BIOMEDICAL RESEARCH INSTITUTE (LBRI) IS A PRIVATE, BIOMEDICAL RESEARCH ORGANIZATION DEDICATED TO IMPROVING PUBLIC HEALTH THROUGH RESEARCH ON THE PREVENTION, TREATMENT AND CURE OF DISEASES. LBRI IS COMMITTED TO CURING DISEASES THROUGH RESEARCH AIMED AT UNDERSTANDING THEIR CAUSES AND BIOLOGICAL MECHANISMS; ASSESSING AND ELIMINATING EXPOSURES TO RESPIRATORY, NEUROLOGICAL AND OTHER HEALTH HAZARDS; AND DEVELOPING IMPROVED THERAPEUTICS, VACCINES, AND DIAGNOSTICS. LBRI IS BASED IN ALBUQUERQUE, NEW MEXICO. 13 12 493 13 0 0 12922849 8132918 74903418 62508220 1371114 831491 58247 35327 89255628 71507956 0 0 0 0 31978794 25557620 0 0 0 48383936 40630837 80362730 66188457 8892898 5319499 189542168 184740544 60247201 64134425 129294967 120606119 X THE LOVELACE BIOMEDICAL RESEARCH INSTITUTE (LBRI) IS A PRIVATE, BIOMEDICAL RESEARCH ORGANIZATION DEDICATED TO IMPROVING PUBLIC HEALTH THROUGH RESEARCH ON THE PREVENTION, DIAGNOSIS, TREATMENT AND CURE OF DISEASES. LBRI IS DEDICATED TO THE DISCOVERY AND ADVANCEMENT OF CLINICAL SOLUTIONS FOR PREVENTION, DIAGNOSIS, TREATMENT AND CURING DISEASES THROUGH RESEARCH. THE RESEARCH IS AIMED AT UNDERSTANDING THEIR CAUSES AND BIOLOGICAL MECHANISMS; ASSESSING AND ELIMINATING EXPOSURES TO RESPIRATORY, NEUROLOGICAL AND OTHER HEALTH HAZARDS; MENTAL ILLNESS; TRAUMATIC BRAIN INJURY AND OTHER BRAIN DISORDERS; AND DEVELOPING IMPROVED THERAPEUTICS, VACCINES, AND DIAGNOSTICS. LBRI IS BASED IN ALBUQUERQUE, NEW MEXICO. 0 0 53374283 0 62508220 MEDICAL RESEARCH AND EDUCATIONAL ACTIVITY IN THE AREAS OF BASIC BIOMEDICAL RESEARCH, HEALTH AND POPULATION STUDIES, INCLUDING RESPIRATORY DISEASES SUCH AS ASTHMA, COPD, ALLERGY AND TOXIC EFFECTS OF ENVIRONMENTAL FACTORS. ADDITIONAL AREAS INCLUDE NEUROLOGIC CONDITIONS SUCH AS TRAUMATIC BRAIN INJURY, ADDICTION AND PSYCHOPATHY. 53374283 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 121 0 1 493 1 1 1 0 0 0 0 0 0 0 0 0 0 0 X 13 12 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NM X X SHANNON TOMA 5053489361 2425 RIDGECREST DRIVE SE ALBUQUERQUE NM 87108 ROBERT RUBIN PHD CEO, PRESIDENT, DIRECTOR 38.00 0.50 X X 903937 0 117843 JACKIE LOVELACE JOHNSON CHAIRWOMAN OF THE BOARD 2.00 X X 0 0 0 JANE DELGADO DIR VICE CHAIR OF NOMINATING COMMITTEE 2.00 X X 0 0 0 CHRIS SPENCER CPA DIR CHAIR BUDGET & FINANCE COMMITTEE 2.00 X X 0 0 0 PAMELA SULLIVAN DIR CHAIR AUDIT & COMPENSATION COMMITTEE 2.00 X X 0 0 0 GREGORY DOWNEY MD DIRECTOR 2.00 X 0 0 0 J GRANT BURCHAM DIRECTOR 2.00 X 0 0 0 MAJOR GENERAL JOHN DOESBURG DIRECTOR 2.00 X 0 0 0 MELVIN TWIEST MD DIRECTOR 2.00 X 0 0 0 SARA EASTERSON-BOND DIRECTOR 2.00 X 0 0 0 TESS BURLESON DIRECTOR 2.00 X 0 0 0 RICHARD GILL PHD DIRECTOR (THRU 4/25/22) 2.00 X 0 0 0 SANDRA CHAVEZ DIRECTOR 2.00 X 0 0 0 TERRY DUNLAY DIRECTOR 2.00 X 0 0 0 SHANNON TOMA TREASURER EXEC VP, COO/CFO 40.00 0.50 X 748043 0 38617 FRANCES FULPS-LAUR ASSISTANT SECRETARY (THRU 2/28/22) 6.00 X 106135 0 20785 JACOB MCDONALD VP, APPLIED SCIENCE 40.00 X 404394 0 41709 DAVID FLANDERS VP, HUMAN RESOURCES 40.00 X 312114 0 34896 STEVEN BELINSKY VP ACADEMIC RESEARCH / SR. SCIENTIST 40.00 X 448203 0 38343 KENT KIEHL EXECUTIVE SCIENCE OFFICER 40.00 X 371711 0 38646 ANDREW MAYER VP, INTERDISCIPLINARY SCIENCE 40.00 X 267726 0 40543 EDWARD BARRETT SR. DIRECTOR, PHARMACOLOGY 40.00 X 251634 0 38725 3813897 0 410107 47 0 1 0 SDV CONSTRUCTION INC 6436 EDITH BLVD NE ALBUQUERQUE NM 87107 CONSTRUCTION SERVICES 438585 SUMMIT CONSTRUCTION INC PO BOX 25703 ALBUQUERQUE NM 87125 CONSTRUCTION SERVICES 426473 UNIVERSAL PROTECTION SERVICES LP 161 WASHINGTON STREET SUITE 600 CONSHOHOCKEN PA 19428 OUTSOURCED SECURITY SERVICES 393123 KCAS LLC 12400 SHAWNEE MISSION PARKWAY SHAWNEE KS 66216 DATA ANALYSIS 310530 KPMG LLP PO BOX 120754 DEPT 0754 DALLAS TX 753120754 AUDIT SERVICES 201175 8 8123306 9612 8132918 BIOMEDICAL RESEARCH 541700 52398484 52398484 PROGRAM SERVICE CHARGE 541700 10109736 10109736 62508220 1283511 1283511 26911 26911 5068222 5477757 42485 -409535 -42485 -452020 -452020 8416 8416 8416 71507956 62508220 0 866818 X 1746390 348898 1397492 16444246 12974510 3469736 1380602 1086534 294068 4540840 3573641 967199 1445542 1137642 307900 226269 226269 424103 424103 47160 47160 70818 70818 6665555 4788903 1876652 96957 76790 20167 300361 232479 67882 1084998 650999 433999 2614387 2060137 554250 256093 88608 167485 174331 137198 37133 556716 556716 3631342 3086641 544701 666266 508361 157905 RESEARCH SUPPLIES 18090944 18090944 REPAIRS AND MAINTENANCE 4315545 3400649 914896 NON-CAPITAL EQUIPMENT 959671 704399 255272 BAD DEBT 365224 365224 84097 61726 22371 66188457 53374283 12814174 0 35394 28325 10735139 2543440 18922309 29502831 74725 0 1133309 1741208 144461277 64105645 79951548 80355632 76615977 58195762 5203739 2073767 7169607 189542168 184740544 13402742 10166168 24826671 28817310 20181329 17116080 1836459 8034867 60247201 64134425 X 129294967 120606119 129294967 120606119 189542168 184740544 5319499 -14008347 0 X 0 1 X 1 1 1 X 52159 31 14011130 12922849 8132918 35119087 52159 31 14011130 12922849 8132918 35119087 35119087 1500113 1912832 1629091 1550631 1283511 7876178 31612 40654 72266 -147651 120643 54887 17593 8416 53888 43121419 226909726 0.81440 0.77640 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - 2017 AMOUNT: $ 4,698. 2018 AMOUNT: $ 120,643. 2019 AMOUNT: $ 27,144. 2020 AMOUNT: $ 17,593. 2021 AMOUNT: $ 8,416. HIGH WAGE TAX CREDIT - OTHER INCOME REBATES - TECHNOLOGY TAX CREDIT - CORPORATE ALLOCATION - BAD DEBT RECOVERY - 2019 AMOUNT: $ 27,743. LOSS ON JOINT VENTURES - 2017 AMOUNT: $ -152,349. PART II, SECTION A. COLUMN (E) THE YEAR 2021, WITH AMOUNTS IN COLUMN (E) IS FOR A SHORT YEAR, SEPTEMBER 25, 2021, TO JUNE 30, 2022. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 47160 47160 66141297 66188457 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 1069 5080 62880 47160 116189 250000 250000 250000 250000 1000000 1500000 104544 1110456 1215000 105241968 35486200 69755768 647105 644426 2679 32666252 24853581 7812671 4690952 3121438 1569514 80355632 DEFERRED COMP 457(B) AND 457(F) 1899564 RIGHT OF USE LEASE LIABILITIES 5270042 CAPITAL LEASE DEBT 865261 8034867 X PART X, LINE 2: LBRI IS AN ENTITY EXEMPT FROM FEDERAL INCOME TAXES ON RELATED INCOME UNDER SECTION 501(A) OF THE INTERNAL REVENUE CODE (IRC) OF 1986, AS AMENDED, AS AN ORGANIZATION DESCRIBED IN IRC SECTION 501(C)(3). FURTHER, LBRI, HAS BEEN CLASSIFIED AS AN ORGANIZATION THAT IS NOT A PRIVATE FOUNDATION UNDER IRC SECTION 509(A) AS DESCRIBED IN IRC SECTION 170(B)(1)(A)(VI), AND AS SUCH, CONTRIBUTIONS TO LBRI QUALIFY AS CHARITABLE CONTRIBUTIONS. HOWEVER, INCOME GENERATED FROM CERTAIN ACTIVITIES UNRELATED TO LBRI'S TAX-EXEMPT PURPOSE IS SUBJECT TO TAX AS UNRELATED BUSINESS INCOME UNDER IRC SECTION 511. AS OF JUNE 30, 2022, THE COMPANY PERFORMED A REVIEW OF ITS MATERIAL TAX POSITIONS IN ACCORDANCE WITH RECOGNITION AND MEASUREMENT STANDARDS ESTABLISHED BY US GAAP. AS A RESULT OF THIS REVIEW, THE COMPANY CONCLUDED THAT LBRI HAD NO UNREPORTED INCOME DERIVED FROM UNRELATED BUSINESS ACTIVITIES AND NO ENTITY LEVEL TAX POSITIONS THAT WOULD NOT MEET THE MORE LIKELY THAN NOT THRESHOLD. THE COMPANY FILES TAX RETURNS AS PRESCRIBED BY THE TAX LAWS OF THE JURISDICTIONS IN WHICH IT OPERATES. IN THE NORMAL COURSE OF BUSINESS, THE COMPANY IS SUBJECT TO EXAMINATION BY FEDERAL, STATE, LOCAL, AND FOREIGN JURISDICTIONS, WHERE APPLICABLE. THE COMPANY RECOGNIZES INTEREST ACCRUED RELATED TO UNRECOGNIZED TAX BENEFITS IN INTEREST EXPENSE AND PENALTIES IN OPERATING EXPENSES IN THE CONSOLIDATED STATEMENT OF ACTIVITES. THERE WERE NO SUCH INTEREST OR PENALTIES RECORDED FOR THE YEARS ENDED SEPTEMBER 25, 2021 THROUGH JUNE 30, 2022. X 1 1 X X X 0 1 0 0 0 0 0 1 0 ROBERT RUBIN PHD CEO, PRESIDENT, DIRECTOR 786021 0 50000 0 67916 0 108466 0 9377 0 1021780 0 0 0 SHANNON TOMA TREASURER EXEC VP, COO/CFO 648043 0 100000 0 0 0 28381 0 10236 0 786660 0 0 0 STEVEN BELINSKY VP ACADEMIC RESEARCH / SR. SCIENTIST 348203 0 100000 0 0 0 28381 0 9962 0 486546 0 0 0 JACOB MCDONALD VP, APPLIED SCIENCE 304394 0 100000 0 0 0 28381 0 13328 0 446103 0 0 0 KENT KIEHL EXECUTIVE SCIENCE OFFICER 363711 0 8000 0 0 0 28381 0 10265 0 410357 0 0 0 DAVID FLANDERS VP, HUMAN RESOURCES 266914 0 45200 0 0 0 28381 0 6515 0 347010 0 0 0 ANDREW MAYER VP, INTERDISCIPLINARY SCIENCE 252726 0 15000 0 0 0 27211 0 13332 0 308269 0 0 0 EDWARD BARRETT SR. DIRECTOR, PHARMACOLOGY 231634 0 20000 0 0 0 25349 0 13376 0 290359 0 0 0 PART I, LINE 4B ROBERT RUBIN 457(F) PLAN - 2021 CONTRIBUTION IS $67,915.68. SINCE DR. RUBIN IS VESTED IN THE 457(F) PLAN, THE ENTIRE AMOUNT OF HIS 2021 457(F) PLAN CONTRIBUTION IS INCLUDED IN TAXABLE INCOME. PART I, LINE 7 BONUSES ARE AWARDED ANNUALLY. MANAGEMENT IS PROVIDED AN AMOUNT, APPROVED BY THE BOARD, TO PAY IN ANNUAL BONUS. BONUS PAYMENTS ARE REVIEWED AND APPROVED BY THE EMPLOYEE'S DIRECT SUPERVISOR, HEAD OF HUMAN RESOURCES, AND CEO. CEO BONUS IS ESTABLISHED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS AND FURTHER APPROVED BY THE FULL BOARD OF DIRECTORS. 990, PART I THE ORGANIZATION IS REQUESTING A CHANGE IN ACCOUNTING PERIOD. REVENUE PROCEDURE 85-58 RULES APPLY. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PRESENTED IN DRAFT FORM TO THE AUDIT AND COMPENSATION COMMITTEE AND TO THE FULL BOARD FOR REVIEW PRIOR TO SUBMISSION. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION HAS A CODE OF CONDUCT THAT ADDRESSES CONFLICTS OF INTEREST. IT IS PRESENTED TO THE BOARD ANNUALLY. ADDITIONALLY, ALL EMPLOYEES, INCLUDING OFFICERS, ARE REQUIRED TO READ AND ACKNOWLEDGE THE CODE ANNUALLY. IN ADDITION, IF A CONFLICT ARISES, THE CONFLICTED INDIVIDUAL RECUSES HIMSELF FROM VOTING ON THE ISSUE. FORM 990, PART VI, SECTION B, LINE 15 THE ORGANIZATION'S AUDIT AND COMPENSATION COMMITTEE RECEIVES COMPENSATORY RECOMMENDATION FROM HUMAN RESOURCES AND FROM MANAGEMENT AS TO: 1. PERCENT BASE SALARY INCREASE FOR THE ORGANIZATION AS A WHOLE WITH TARGETS AND THE DOLLAR AMOUNT OF IMPACT ARE PRESENTED TO AND APPROVED BY THE AUDIT AND COMPENSATION COMMITTEE. 2. TARGET AMOUNT OF BONUS COMPENSATION FOR THE ENTIRE ORGANIZATION AND THE DOLLAR IMPACT ARE PRESENTED AND APPROVED BY THE AUDIT AND COMPENSATION COMMITTEE. 3. CEO COMPENSATION (BASE, BONUS AND DEFERRED COMPENSATION) IS REVIEWED TO MARKET VALUE FOR SIMILAR POSITIONS IN THE INDUSTRY AND APPROVED BY THE AUDIT AND COMPENSATION COMMITTEE. THIS PROCESS IS DOCUMENTED AND WAS LAST COMPLETED IN OCTOBER 2022. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE PROVIDED UPON REQUEST. FORM 990, PART IX, LINE 11G SUBCONTRACTORS: PROGRAM SERVICE EXPENSES 2,311,373. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 2,311,373. PROFESSIONAL SERVICES: PROGRAM SERVICE EXPENSES 2,477,530. MANAGEMENT AND GENERAL EXPENSES 1,876,652. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 4,354,182. LOVELACE SCIENTIFIC RESOURCES 2441 RIDGECREST DR SE ALBUQUERQUE NM 87108 850357767 CLINICAL TRIAL REASEARCH NM LOVELACE BIOMEDICAL RESEARCH INSTITUTE C 399310 44679 1.00000 1 0 0 0 1 0 0 0 0 0 0 0 0 1 1 1 1 1 0 0 LOVELACE SCIENTIFIC RESOURCES D 682763 FMV